A plant, a compound, a ceremony
Ibogaine is a psychoactive alkaloid found naturally in the root bark of Tabernanthe iboga, a shrub native to the rainforests of Central Africa — particularly Gabon and Cameroon. It belongs to a class of compounds called indole alkaloids, and it produces effects unlike those of any other known psychoactive substance.
For centuries, the Bwiti people of Gabon have used iboga root bark in initiation ceremonies and healing rituals. In high doses, it induces a profound visionary state — described by those who have experienced it as an encounter with memory, identity, and the unconscious — lasting up to 36 hours. This is not a recreational experience. It is, in the Bwiti tradition, a rite of passage undertaken once or rarely in a lifetime.
Western science first isolated ibogaine from the plant in 1901. In the mid-20th century it was briefly sold in France as a low-dose stimulant under the name Lambarène. Its potential in treating addiction was discovered accidentally in 1962 by Howard Lotsof, a 19-year-old heroin addict in New York, who noticed that after taking ibogaine his craving and withdrawal symptoms had dramatically diminished. That observation set in motion decades of research, controversy, and underground treatment — and eventually the mainstream scientific attention ibogaine receives today.
Worth knowing
Ibogaine is not derived from a single plant species. It can also be found in Voacanga africana, which is the primary source used in pharmaceutical-grade production today — partly because harvesting T. iboga root in the wild is environmentally unsustainable and the plant grows slowly.
How is it different from other psychedelics?
Ibogaine is often grouped with psychedelics such as psilocybin, LSD, or ayahuasca, but this comparison is misleading. Its mechanism of action in the brain is fundamentally different, its effects are qualitatively distinct, and its duration — 18 to 36 hours for a full dose — is far longer than any of these substances.
Unlike classical psychedelics, which work primarily through the serotonin 5-HT2A receptor, ibogaine interacts with a wide range of neurological systems simultaneously — including opioid receptors, serotonin transporters, sigma receptors, and NMDA receptors. This complexity is part of why its effects are so different, and why its pharmacology has been difficult to fully understand.
Visually, ibogaine produces what researchers describe as an oneirogenic (dream-inducing) state — vivid imagery experienced like watching a film or slideshow, often with strongly autobiographical content. People frequently report revisiting memories and experiences from their past, sometimes with a feeling of emotional clarity or resolution. This is distinct from the perceptual distortions typical of LSD or psilocybin.
Its major active metabolite, noribogaine, persists in the body for 24 to 50 hours after ibogaine itself has cleared. Noribogaine acts primarily as a serotonin reuptake inhibitor — similar in some respects to an antidepressant — and is thought to contribute significantly to ibogaine's longer-term effects, including its reported impact on mood and craving.
The three phases of an ibogaine experience
At a full therapeutic or ceremonial dose (typically 10–20 mg/kg of body weight), ibogaine produces a structured, multi-phase experience that unfolds over one to three days. Understanding these phases is important for anyone seeking to understand ibogaine — whether for treatment, research, or journalism.
Hours 1–8
The Visionary Phase
Vivid, dream-like visual imagery — often described as autobiographical film sequences. Strong physical effects including nausea, balance disturbance, and sensitivity to light and sound. Emotional intensity is high. The person is typically immobile and should be supervised continuously.
Onset 1–3 hours · Duration 4–8 hours
Hours 8–36
The Introspective Phase
Visual imagery fades. The person enters a period of deep reflection and cognitive processing. Insomnia is typical. Lingering effects include nausea, headache, and mood changes. Some people experience a period of low mood — sometimes called the "grey day" — which can persist for days after treatment.
Onset 4–8 hours · Duration 8–20 hours
Days 2–4+
Residual Stimulation
A period of alertness, reduced need for sleep, and continued psychological processing. Most people describe a window of unusual clarity or calm. For those treated for addiction, this period is considered therapeutically significant — cravings are often reported as absent or greatly reduced.
Onset 12–24 hours · Duration 24–72 hours or longer
Why is it being studied for addiction?
Ibogaine's most discussed potential application is the treatment of opioid use disorder and other substance dependencies. The clinical interest stems from a consistent pattern seen across case reports and observational studies: a single dose of ibogaine appears to significantly reduce or eliminate opioid withdrawal symptoms, and to interrupt drug-seeking behavior for days, weeks, or sometimes months afterward.
No existing approved treatment does this. Methadone and buprenorphine manage withdrawal and craving but require ongoing daily use. Ibogaine, if its effects are confirmed in rigorous trials, would represent something categorically different — a one-time or infrequent intervention that interrupts the cycle of dependence.
Preliminary results from a 2023 Stanford University study of military veterans with PTSD and traumatic brain injury showed significant reductions in PTSD symptoms, depression, and disability after ibogaine treatment in a supervised clinic in Mexico. This study attracted substantial media attention and contributed to the momentum behind the 2025 Texas funding initiative and the 2026 US executive order directing federal agencies to accelerate ibogaine research.
However, the evidence base remains limited. Only two randomized controlled trials have been completed on ibogaine and its metabolite noribogaine for substance use disorders. Systematic reviews from 2022 and 2023 describe promising signals but confirm that safety and efficacy are not yet established at the standard required for regulatory approval.
A note on safety — please read
Ibogaine carries serious and well-documented risks, particularly to the heart. It can prolong the QT interval — an electrical measurement in the cardiac cycle — in ways that can lead to life-threatening arrhythmias. Deaths have been associated with its use, including in clinical settings.
These risks are manageable under proper medical supervision, with thorough cardiac screening before treatment and continuous monitoring during it. They are not manageable in unsupervised settings.
This site does not recommend ibogaine treatment. It provides information so that people can make informed decisions and ask the right questions. For a full safety overview, see our Safety & Medical Considerations page.
Is ibogaine legal?
Legal status varies significantly by country and is changing rapidly. In the United States, ibogaine is classified as a Schedule I controlled substance under the Controlled Substances Act — meaning it is federally illegal, though some cities and states have taken steps toward decriminalization of psychedelics more broadly. A 2026 executive order directed US agencies to accelerate research, regulatory review, and potential pathways to patient access.
In Canada ibogaine is legal. In New Zealand it requires a prescription. In the United Kingdom it falls under the Psychoactive Substances Act. Treatment clinics operate legally or in legal gray areas in Mexico, the Bahamas, the Netherlands, South Africa, Costa Rica, and New Zealand, among others.
For a full country-by-country breakdown, see our Legal Status page.